tetano
Editor, Senior Moderator
Mol Ther
. 2022 Feb 12;S1525-0016(22)00096-X.
doi: 10.1016/j.ymthe.2022.02.013. Online ahead of print.
Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy
Olga Minenkova[SUP] 1 [/SUP], Daniela Santapaola[SUP] 1 [/SUP], Ferdinando Maria Milazzo[SUP] 1 [/SUP], Anna Maria Anastasi[SUP] 1 [/SUP], Gianfranco Battistuzzi[SUP] 1 [/SUP], Caterina Chiapparino[SUP] 1 [/SUP], Antonio Rosi[SUP] 1 [/SUP], Giuseppe Gritti[SUP] 2 [/SUP], Gianmaria Borleri[SUP] 2 [/SUP], Alessandro Rambaldi[SUP] 3 [/SUP], Clélia Dental[SUP] 4 [/SUP], Cécile Viollet[SUP] 4 [/SUP], Bruno Pagano[SUP] 5 [/SUP], Laura Salvini[SUP] 6 [/SUP], Emanuele Marra[SUP] 7 [/SUP], Laura Luberto[SUP] 7 [/SUP], Antonio Rossi[SUP] 8 [/SUP], Anna Riccio[SUP] 9 [/SUP], Emilio Merlo Pich[SUP] 1 [/SUP], Maria Gabriella Santoro[SUP] 10 [/SUP], Rita De Santis[SUP] 11 [/SUP]
Affiliations
Abstract
As of December 2021, coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains global emergency and novel therapeutics are urgently needed. Here we describe human single chain variable fragment (scFv) antibodies (76clAbs) that block an epitope of the SARS-CoV-2 spike protein essential for ACE2-mediated entry into cells. 76clAbs neutralize the delta variant and other variants being monitored (VBMs) and inhibit spike-mediated pulmonary cell-cell fusion, a critical feature of COVID-19 pathology. In two independent animal models, intranasal administration counteracted the infection. Due to high efficiency, remarkable stability, resilience to nebulization and low cost of production, 76clAbs may become a relevant tool for rapid, self-administrable early intervention in SARS-CoV-2-infected subjects independently of their immune status.
. 2022 Feb 12;S1525-0016(22)00096-X.
doi: 10.1016/j.ymthe.2022.02.013. Online ahead of print.
Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy
Olga Minenkova[SUP] 1 [/SUP], Daniela Santapaola[SUP] 1 [/SUP], Ferdinando Maria Milazzo[SUP] 1 [/SUP], Anna Maria Anastasi[SUP] 1 [/SUP], Gianfranco Battistuzzi[SUP] 1 [/SUP], Caterina Chiapparino[SUP] 1 [/SUP], Antonio Rosi[SUP] 1 [/SUP], Giuseppe Gritti[SUP] 2 [/SUP], Gianmaria Borleri[SUP] 2 [/SUP], Alessandro Rambaldi[SUP] 3 [/SUP], Clélia Dental[SUP] 4 [/SUP], Cécile Viollet[SUP] 4 [/SUP], Bruno Pagano[SUP] 5 [/SUP], Laura Salvini[SUP] 6 [/SUP], Emanuele Marra[SUP] 7 [/SUP], Laura Luberto[SUP] 7 [/SUP], Antonio Rossi[SUP] 8 [/SUP], Anna Riccio[SUP] 9 [/SUP], Emilio Merlo Pich[SUP] 1 [/SUP], Maria Gabriella Santoro[SUP] 10 [/SUP], Rita De Santis[SUP] 11 [/SUP]
Affiliations
- PMID: 35167974
- DOI: 10.1016/j.ymthe.2022.02.013
Abstract
As of December 2021, coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains global emergency and novel therapeutics are urgently needed. Here we describe human single chain variable fragment (scFv) antibodies (76clAbs) that block an epitope of the SARS-CoV-2 spike protein essential for ACE2-mediated entry into cells. 76clAbs neutralize the delta variant and other variants being monitored (VBMs) and inhibit spike-mediated pulmonary cell-cell fusion, a critical feature of COVID-19 pathology. In two independent animal models, intranasal administration counteracted the infection. Due to high efficiency, remarkable stability, resilience to nebulization and low cost of production, 76clAbs may become a relevant tool for rapid, self-administrable early intervention in SARS-CoV-2-infected subjects independently of their immune status.